论文部分内容阅读
为探讨恶性疾病相关性DNA结合蛋白2（MAD2）在肝癌诊断中的价值，采用ELISA法检测了27例原发性肝癌、14例转移性肝癌和12例正常对照组血浆中MAD2的浓度。原发性肝癌、转移性肝癌及正常对照组血浆中MAD2的浓度分别为（30.56±11.38）μg/ml、（9.27±5.58）μg/ml和（8.43±5.62）μg/ml。原发性肝癌患者MAD2浓度明显高于转移性肝癌患者和正常对照组(P<0.001)，转移性肝癌患者和正常对照组MAD2浓度无显著性差异(P>0.05)。结果提示：MAD2在原发性肝癌的诊断中可能是一个有价值的诊断指标。
To investigate the value of MAD2 in the diagnosis of hepatocellular carcinoma, the concentration of MAD2 in plasma of 27 cases of primary hepatocellular carcinoma, 14 cases of metastatic hepatocellular carcinoma and 12 cases of normal control was detected by ELISA. The concentrations of MAD2 in primary liver cancer, metastatic liver cancer and normal control group were (30.56 ± 11.38) μg / ml, (9.27 ± 5.58) μg / ml and (8.43 ± 5.62) μg / ml, respectively. The concentration of MAD2 in patients with primary liver cancer was significantly higher than that in patients with metastatic liver cancer and normal controls (P <0.001). There was no significant difference in MAD2 between patients with metastatic liver cancer and normal controls (P> 0.05). The results suggest that MAD2 may be a valuable diagnostic marker in the diagnosis of primary liver cancer.